Nektar Therapeutics (NASDAQ:NKTR) Reaches New 52-Week High - Here's Why

Key Points

• Shares rallied to a new 52‑week high, trading as high as $77.00 (last $75.60) while Wall Street remains largely bullish — nine Buy ratings and an average price target of $128.13, with several firms lifting targets into the $140–$151 range.
• Significant legal risk has emerged: Pomerantz filed a securities class action and multiple plaintiff firms and investor alerts cite alleged misrepresentations about REZOLVE‑AA patient enrollment, with a May 5, 2026 lead‑plaintiff deadline that heightens litigation visibility.
• Nektar beat quarterly expectations (loss per share of $1.78 vs. consensus loss of $2.69 and revenue $21.8M vs. $10.4M) but remains deeply unprofitable (negative net margin ~297% and ROE ~-386%), and insiders have sold shares recently.

Shares of Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) hit a new 52-week high during trading on Wednesday . The stock traded as high as $77.00 and last traded at $75.60, with a volume of 43011 shares trading hands. The stock had previously closed at $72.96.

Trending Headlines about Nektar Therapeutics

Here are the key news stories impacting Nektar Therapeutics this week:

• Neutral Sentiment: Wedbush initiated coverage of NKTR with a Neutral rating and a $70 price target, implying modest downside from recent prices and signaling limited near‑term analyst upside. Wedbush coverage
• Neutral Sentiment: Reported short‑interest data in late March shows anomalous zero/NaN values across filings (likely a data/reporting error); this does not provide a clear bearish or bullish signal. Monitor updated short‑interest reports for confirmation.
• Negative Sentiment: Pomerantz LLP filed a securities class action against Nektar and certain officers alleging violations of federal securities laws for purchases between Feb 26, 2025 and Dec 15, 2025 — a formal complaint that increases legal risk and potential liability exposure. Pomerantz filing
• Negative Sentiment: Levi & Korsinsky issued an investor alert focusing on alleged misrepresentations about REZOLVE‑AA patient enrollment compliance — the substantive allegation that underpins many of the class action claims and is likely a primary driver of investor concern. Levi & Korsinsky alert
• Negative Sentiment: Multiple national plaintiff firms (Rosen, Schall, Bronstein Gewirtz, Bernstein Liebhard, Robbins, Faruqi & Faruqi, Glancy, Gross, etc.) have issued notices urging NKTR investors to seek lead‑plaintiff status before the May 5, 2026 deadline — amplifying litigation visibility and the chance of coordinated claims. Representative notices: Rosen (Newsfile), Schall (GlobeNewswire). Rosen notice Schall notice

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on NKTR. TD Cowen assumed coverage on shares of Nektar Therapeutics in a research note on Tuesday, March 17th. They issued a "buy" rating on the stock. BTIG Research raised their price target on shares of Nektar Therapeutics from $118.00 to $151.00 and gave the company a "buy" rating in a research report on Tuesday, February 10th. Citigroup boosted their price objective on shares of Nektar Therapeutics from $102.00 to $123.00 and gave the stock a "buy" rating in a report on Monday, March 16th. Oppenheimer reaffirmed an "outperform" rating and issued a $140.00 price objective on shares of Nektar Therapeutics in a research report on Friday, March 13th. Finally, B. Riley Financial reissued a "buy" rating and issued a $150.00 target price (up from $105.00) on shares of Nektar Therapeutics in a report on Monday, February 23rd. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $128.13.

Nektar Therapeutics Stock Performance

The business's fifty day moving average price is $58.05 and its 200-day moving average price is $55.46. The stock has a market cap of $2.16 billion, a PE ratio of -7.43 and a beta of 1.16.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last released its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, beating the consensus estimate of ($2.69) by $0.91. Nektar Therapeutics had a negative net margin of 297.07% and a negative return on equity of 386.16%. The firm had revenue of $21.81 million during the quarter, compared to analysts' expectations of $10.44 million. Analysts forecast that Nektar Therapeutics will post -0.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Jonathan Zalevsky sold 3,867 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $35.67, for a total transaction of $137,935.89. Following the transaction, the insider directly owned 21,354 shares of the company's stock, valued at $761,697.18. This represents a 15.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Howard W. Robin sold 423 shares of Nektar Therapeutics stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $73.00, for a total value of $30,879.00. Following the completion of the sale, the chief executive officer directly owned 75,489 shares of the company's stock, valued at $5,510,697. The trade was a 0.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 4,470 shares of company stock valued at $181,955. Company insiders own 3.71% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of NKTR. Emerald Mutual Fund Advisers Trust bought a new position in shares of Nektar Therapeutics in the 3rd quarter worth approximately $13,269,000. Simplify Asset Management Inc. grew its position in Nektar Therapeutics by 67.6% during the third quarter. Simplify Asset Management Inc. now owns 87,174 shares of the biopharmaceutical company's stock valued at $4,960,000 after buying an additional 35,176 shares during the period. Emerald Advisers LLC purchased a new stake in Nektar Therapeutics during the third quarter valued at approximately $18,393,000. Moody Aldrich Partners LLC increased its holdings in Nektar Therapeutics by 62.3% during the third quarter. Moody Aldrich Partners LLC now owns 73,716 shares of the biopharmaceutical company's stock valued at $4,194,000 after buying an additional 28,304 shares during the last quarter. Finally, Farallon Capital Management LLC bought a new position in Nektar Therapeutics in the third quarter worth approximately $45,008,000. 75.88% of the stock is owned by hedge funds and other institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics NASDAQ: NKTR is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body's immune system to treat cancer and other serious diseases.

Nektar's product portfolio and pipeline include a range of clinical-stage and partnered programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.